NGM Bio (NGM) news on their NASH drug candidate | Biotech Message Board Posts

Biotech   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  28397 of 28593  at  10/7/2019 9:36:03 AM  by

Biotech_Jim


NGM Bio (NGM) news on their NASH drug candidate

 

--Treatment with aldafermin 1 mg resulted in statistically significant reductions in absolute and relative liver fat at 24 weeks compared to placebo --

-- Statistically significant improvements also observed across key non-invasive biomarkers of metabolism, inflammation and fibrosis, with favorable tolerability profile --

-- Full 24-week 1 mg Cohort 4 data, including biopsy assessments, anticipated in Q1 2020 --

My concerns with the approach and the data are:
 
1)  injectable
2)  LFT elevations
3)  LDL elevation
4)  Liver fat content drop does not appear to continuous over time (12 vs 24 weeks), incomplete data disclosure for all trt groups also
 
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 6     Views: 154
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board


About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...